Latest News
Get real-time updates on the latest news and developments in the pharmaceutical world. Stay informed about new drug launches, research findings, regulatory changes, and industry updates. Explore a wide range of topics and stay connected with the rapidly evolving world of pharma.
Astrazeneca Suffers Setback As FDA Rejects Ultomiris For Rare Autoimmune Disease
AstraZeneca’s plans to expand the use of Ultomiris in the United States have encountered a setback, as the FDA issued ...
Abbott Partners With Bigfoot Biomedical To Integrate Diabetes Devices
Abbott has made a significant move by acquiring Bigfoot Biomedical, a diabetes management technology maker. While the financial terms of ...
Medicare Price Negotiations Could Slash Biotech R&D Spending, Gilead-Funded Study Warns
The Inflation Reduction Act (IRA) is projected to have a more significant impact on pharmaceutical research and development (R&D) than ...
Moderna Claims New COVID-19 Vaccine Can Protect Against Pirola Variant
Moderna is vigorously advocating for the expedited approval of its updated COVID-19 vaccine in preparation for the upcoming fall vaccination ...
J&J Gives Up On $230M Blood Pressure Drug After Disappointing Trial Results
Johnson & Johnson (J&J) is stepping back from its $230 million investment in a blood pressure treatment, aprocitentan, and returning ...
Nimbus Raises $210M To Advance Small Molecule Pipeline, Honors Late Founder
Nimbus Therapeutics, with its experienced leadership, well-established R&D platform, and substantial financing, appears well-positioned for success in the public markets. ...
Kriya Acquires Gene Therapy Biotech To Enter NASH Market With Novel Approach
Kriya Therapeutics, a prominent player in the biotech industry, has continued its acquisition spree, this time securing Tramontane Therapeutics to ...
GSK Teams Up With Ex-Basketball Star To Raise Awareness Of RSV, A Deadly Virus For Babies
GSK is intensifying its campaign to raise awareness about respiratory syncytial virus (RSV) and promote its RSV vaccine, Arexvy. The ...
Seagen, Genmabās Tivdak shows survival benefit in cervical cancer phase 3 trial
Amidst the Federal Trade Commission’s close scrutiny of Pfizer’s monumental $43 billion acquisition of Seagen, there’s a significant breakthrough in ...
Novartis sues U.S. government over IRA price negotiations for Entresto
Novartis has taken legal action against the U.S. government in response to the Inflation Reduction Act (IRA), becoming the latest ...
NestlƩ abandons $2 billion peanut allergy drug Palforzia after disappointing sales and safety issues
NestlƩ has completed the sale of its peanut allergy drug, Palforzia, to the U.S.-based allergy specialist Stallergenes Greer for an ...
Tonixās long COVID drug fails in pain but shows promise in fatigue
Tonix Pharmaceuticals’ experimental treatment for long COVID with fibromyalgia-like symptoms, TNX-102 SL, did not demonstrate a statistically significant improvement in ...
CanSino Biologics eyes more mRNA vaccine deals after AstraZeneca pact
CanSino’s recent collaboration with AstraZeneca in mRNA manufacturing is just the beginning of their ambitions in this field, according to ...
BioCardiaās cell therapy fails to improve heart failure outcomes in Phase 3 trial
BioCardia’s attempts to revive its paused phase 3 heart failure trial have hit a major setback, as results fail to ...
Star Therapeutics raises $90M to expand its portfolio of antibody therapies for unmet needs
Star Therapeutics has secured an impressive $90 million in funding, a testament to its commitment to advancing its portfolio companies ...
BMS acquires regional rights to Zenasā obexelimab, a bifunctional antibody for autoimmune diseases
Zenas BioPharma has made a strategic move by transferring regional rights for its bifunctional monoclonal antibody, obexelimab. Bristol Myers Squibb ...
Amgenās Otezla holds its ground against BMSā Sotyktu in oral plaque psoriasis market, leaving room for J&Jās potential game-changer
Amgen’s bold $13.4 billion investment in Otezla appears to remain robust in the face of competition from Bristol Myers Squibb’s ...
A Breakthrough Drug for Metastatic Renal Cancer and Dialysis Patients
Oncorena has achieved a significant milestone by administering the first treatment to a patient in their Phase I/II trial of ...
How a New Drug Could Restore Brain Function After Stroke
Addex Therapeutics has made a significant stride in the field of drug discovery and development. Their recent findings, featured in ...
BioNTech and DualityBio Advance Novel HER2-low Breast Cancer Drug to Phase III Trial
BioNTech, the renowned name behind the COVID-19 vaccine breakthrough, is venturing into uncharted territory with its licensed antibody-drug conjugate (ADC), ...
Alvotech Seeks Interchangeability Status for Humira Biosimilar Again
Alvotech is forging an audacious path towards a potential game-changer. CEO Robert Wessman recently unveiled a resubmission of their Biologics ...
Bavarian Nordic Abandons COVID Booster After Failing to Protect Against New Variants
Bavarian Nordic, a Danish biotech firm, has faced a crossroads that shines a light on the ever-evolving nature of the ...
Hugel Resubmits BLA for Its Botulinum Toxin Letybo to the US FDA
Hugel has just rekindled its pursuit of a groundbreaking achievement: the approval of Letybo (letibotulinumtoxinA), a potent botulinum toxin, for ...
Mallinckrodt Launches New FDA-Approved ADHD Drug Lisdexamfetamine
Mallinckrodt, a global specialty pharmaceutical company, has made waves with an announcement that’s set to reshape the Attention-Deficit/Hyperactivity Disorder (ADHD) ...
GSKās Nucala Gets Closer to Approval for Severe Asthma in Japan
GSK has unveiled a ray of hope for millions of Japanese individuals grappling with the debilitating burden of chronic rhinosinusitis ...
Pfizer and BioNTech Get Green Light for Omicron Vaccine in Europe by CHMP
Pfizer and BioNTech have unveiled their latest breakthrough in the post COVID era. Brace yourselves for the Omicron XBB.1.5-adapted monovalent ...
NexImmune slashes staff again as cash crunch looms over its nanoparticle platform
NexImmune, the immunotherapy biotech, is once again in the spotlight for layoff as it nears the end of its financial ...
Sana cuts jobs in research area, keeps mum on numbers and programs
Sana Biotechnology, a company with a focus on CAR-T therapies, has discreetly carried out another round of layoffs, declining to ...
Bayer launches new trials for Kerendia, a potential blockbuster for heart failure
Two summers ago, Bayer introduced Kerendia (finerenone) as a treatment for chronic kidney disease (CKD) linked to type 2 diabetes. ...
Tvardi Therapeutics Begins Phase 2 Trial for Novel IPF Treatment
Tvardi Therapeutics, a clinical-stage biopharmaceutical company dedicated to advancing STAT3 inhibitors, has exciting news to share. They’ve initiated the dosing ...
